Assertio Publishes Study Showing Rolvedon Safe and Effective for Same-Day Dosing with TC Chemotherapy

Reuters01-10

Assertio Publishes Study Showing Rolvedon Safe and Effective for Same-Day Dosing with TC Chemotherapy

Assertio Holdings Inc. has announced the publication of results from a clinical trial investigating same-day dosing of Rolvedon® (eflapegrastim-xnst) injection in patients with early-stage breast cancer undergoing TC chemotherapy (docetaxel and cyclophosphamide). The peer-reviewed results, published in The Oncologist, indicate that same-day administration of Rolvedon demonstrated effective neutrophil recovery and an adverse event profile similar to next-day dosing. The study enrolled 53 patients, with 49 completing the trial, and reported a low incidence of febrile neutropenia and no neutropenic complications. The results have already been published. The benefits of same-day dosing of eflapegrastim-xnst have not been evaluated in a randomized controlled trial.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Assertio Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260109405279) on January 09, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2602305627?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-10 02:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602305627","market":"nz","top_or_hot":-1,"title":"Assertio Publishes Study Showing Rolvedon Safe and Effective for Same-Day Dosing with TC Chemotherapy","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Assertio Publishes Study Showing Rolvedon Safe and Effective for Same-Day Dosing with TC Chemotherapy\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Assertio Holdings Inc. has announced the publication of results from a clinical trial investigating same-day dosing of Rolvedon® (eflapegrastim-xnst) injection in patients with early-stage breast cancer undergoing TC chemotherapy (docetaxel and cyclophosphamide). The peer-reviewed results, published in The Oncologist, indicate that same-day administration of Rolvedon demonstrated effective neutrophil recovery and an adverse event profile similar to next-day dosing. The study enrolled 53 patients, with 49 completing the trial, and reported a low incidence of febrile neutropenia and no neutropenic complications. The results have already been published. The benefits of same-day dosing of eflapegrastim-xnst have not been evaluated in a randomized controlled trial.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Assertio Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260109405279) on January 09, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assertio Publishes Study Showing Rolvedon Safe and Effective for Same-Day Dosing with TC Chemotherapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssertio Publishes Study Showing Rolvedon Safe and Effective for Same-Day Dosing with TC Chemotherapy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-10 02:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Assertio Publishes Study Showing Rolvedon Safe and Effective for Same-Day Dosing with TC Chemotherapy\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Assertio Holdings Inc. has announced the publication of results from a clinical trial investigating same-day dosing of Rolvedon® (eflapegrastim-xnst) injection in patients with early-stage breast cancer undergoing TC chemotherapy (docetaxel and cyclophosphamide). The peer-reviewed results, published in The Oncologist, indicate that same-day administration of Rolvedon demonstrated effective neutrophil recovery and an adverse event profile similar to next-day dosing. The study enrolled 53 patients, with 49 completing the trial, and reported a low incidence of febrile neutropenia and no neutropenic complications. The results have already been published. The benefits of same-day dosing of eflapegrastim-xnst have not been evaluated in a randomized controlled trial.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Assertio Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260109405279) on January 09, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nNDL9Bz7H9:1","article_id":"2602305627","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2602305627","pubTimestamp":1767984313,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Assertio Holdings Inc. has announced the publication of results from a clinical trial investigating same-day dosing of Rolvedon  injection in patients with early-stage breast cancer undergoing TC chemotherapy . The peer-reviewed results, published in The Oncologist, indicate that same-day administration of Rolvedon demonstrated effective neutrophil recovery and an adverse event profile similar to next-day dosing. The study enrolled 53 patients, with 49 completing the trial, and reported a low incidence of febrile neutropenia and no neutropenic complications. The results have already been published. The benefits of same-day dosing of eflapegrastim-xnst have not been evaluated in a randomized controlled trial.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investmen","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","ASRT":"Assertio Holdings, Inc."},"translate_title":"Assertio发表研究表明Rolvedon与TC化疗当天给药安全有效","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ASRT":0.9},"content_text":"Assertio Publishes Study Showing Rolvedon Safe and Effective for Same-Day Dosing with TC Chemotherapy\n    \n\n        Assertio Holdings Inc. has announced the publication of results from a clinical trial investigating same-day dosing of Rolvedon® (eflapegrastim-xnst) injection in patients with early-stage breast cancer undergoing TC chemotherapy (docetaxel and cyclophosphamide). The peer-reviewed results, published in The Oncologist, indicate that same-day administration of Rolvedon demonstrated effective neutrophil recovery and an adverse event profile similar to next-day dosing. The study enrolled 53 patients, with 49 completing the trial, and reported a low incidence of febrile neutropenia and no neutropenic complications. The results have already been published. The benefits of same-day dosing of eflapegrastim-xnst have not been evaluated in a randomized controlled trial.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Assertio Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260109405279) on January 09, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2602305627","isCrawlerRequest":true}